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Background: The NIOX MINO is a nitric oxide (FENO) analyser based on electrochemical tech-
nology. It includes a replaceable sensor. Quality control procedures are recommended, but
regular calibration is not possible. We aimed to evaluate the performance characteristics of
the NIOX MINO to identify if reproducibility changed over time, or with different sensors.
Also, there are reports that reproducibility of FENO may be reduced in patients with high FENO:
our secondary aim was to address this issue.
Methods: Reproducibility in 24 separate sensor-analyser units was calculated on three occa-
sions over two months in 17 patients. These included 9 patients whose FENO was high (mean
80 ppb) and 8 in whom FENO was low (mean 16 ppb).
Results: One device failed quality control testing. For the remaining 23 sensor-analyser combi-
nations, the mean coefficient of variation was 4.0% (range 1.2e7.2%) at baseline, 3.6% (range
2.0e7.0) at one month, and 3.6% (range 1.6e7.6%) at two months. The 95% C.I. for the mean
limits of agreement for FENO was 4.2 ppb (range 0.9e9.6 ppb), 3.8 ppb (range 1.6e6.9 ppb)
and 3.2 ppb (range 1.2e6.8 ppb) respectively (NS). The limits of agreement exceeded the
manufacturer’s specifications (5 ppb) in 0 devices at baseline, 3 (13%) at one month, and 5
(22%) at two months.
Conclusions: Reproducibility of FENO using the NIOX MINO
 was within clinically acceptable
limits (10 ppb) and was generally stable. However, with time, a proportion of individual
sensor-analyser combinations yielded variability outside the manufacturer’s specifications.
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Study population 
n = 17 
(baseline FENO:
>50ppb, n = 9 
<30ppb, n = 8) 
Randomisation 
Group 1, n = 8
(baseline FENO: >50ppb, n = 3; 
<30ppb, n = 5) 
Analysers A-L, sensors 1-12. 
The sensor-analyser 
combinations were used  
without subsequent change 
throughout study. 
Group 2, n = 9
(baseline FENO: >50ppb, n = 6; 
<30ppb, n = 3) 
Analysers A-L, sensors 13-24. 
The sensor-analyser 
combinations were used  
without subsequent change 
throughout study. 
Visit 1 
24 FENO  measurements (2 in 
each of 12 sensor-analyser 
combinations) in randomised 
order.
Visit 1 
24 FENO measurements (2 in 
each of 12 sensor-analyser 
combinations) in randomised 
order.
Visit 3 (two months) 
24 FENO  measurements (2 in 
each of 12 sensor-analyser 
combinations) in randomised 
order.
Visit 2 (one month) 
24 FENO  measurements (2 in 
each of 12 sensor-analyser 
combinations) in randomised 
order.
Visit 3 (two months) 
24 FENO  measurements (2 in 
each of 12 sensor-analyser 
combinations) in randomised 
order.
Visit 2 (one month) 
24 FENO measurements (2 in 
each of 12 sensor-analyser 
combinations) in randomised 
order.
Figure 1 Study design.
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The measurement of the fraction of nitric oxide in exhaled
air (FENO) is an indirect means of assessing airway inflam-
mation.1 FENO levels provide information enabling the
clinician to interpret the aetiology of non-specific respira-
tory symptoms and the potential for steroid response.2 In
asthma, symptoms and airway inflammation may be
discordant,3 and both high and low FENO measurements may
help to discriminate between inflammatory and non-
inflammatory causes of airway symptoms. Serial measure-
ments may allow for a more informed perspective in indi-
vidual patients.4,5
Against this background, there is a need for an inex-
pensive analyser which provides accurate and reproducible
results. Analysers based on chemiluminescence technology
are expensive, and between-analyser differences in
performance characteristics have been reported.6,7 The
NIOX MINO analyser (Aerocrine, Solna, Sweden) is based
on electrochemical FENO measurements.
8 Its performance
in relation to chemiluminescence analysers has been eval-
uated in numerous studies.5,9e19 Correlations between FENO
obtained using the NIOX MINO and the NIOX,5,9,11,14e16,18
the Logan LR2000,17 the Ecomedics CLD88sp10,12,19 and the
Sensormedics NOA13 are highly significant, at approximately
0.95. The limits of agreement across studies vary between
3.718 and 4.8 ppb.9 However, in almost all studies, only
a single NIOX MINO device has been tested. There are no
studies in which multiple devices have been evaluated. In
some, the NIOX MINO has yielded consistently higher FENO
levels than with chemiluminescence analysers.5,10,11,13 In
one report a correction factor was recommended.18 It has
also been reported that reproducibility may be less satis-
factory in patients with high FENO.
15
In contrast to chemiluminescence analysers, the elec-
trochemical technology which supports the NIOX MINO
does not allow for pre-test calibration. Further, each ana-
lyser contains a replaceable sensor, and depending on
specification, individual sensors are changed after 100 or
300 actuations. The sensitivity, precision, accuracy and
measurement range of each sensor is pre-set to comply
with published technical specifications. Thereafter, the
operating instructions for the NIOX MINO include a valida-
tion procedure using biological controls as a reference. This
is designed to ensure that the performance characteristics
conform to the manufacturer’s specifications i.e.  5 ppb
for values <50 ppb, 10% for values >50 ppb (see http://
www.aerocrine.com/en/niox-mino/Specification/).
However, in the absence of regular calibration, the exact
performance characteristics of an analyser might poten-
tially change over time or when a sensor is replaced.
To date, no data reporting the long term performance of
the NIOX MINO have been published, nor are there any
data comparing individual sensors. The aim of the present
study was to assess the long term stability and reproduc-
ibility of FENO measurements using 24 NIOX MINO
 sensor-
analyser devices in patients with both high and low FENO
levels. This information is particularly relevant to clinicians
who are measuring serial FENO measurements to monitor
patients with asthma using the NIOX MINO, and to
researchers using the device in field studies.Subjects and methods
Subjects were non-smokers, and all but one had stable
asthma. The other subject was atopic but asymptomatic
and had a high baseline FENO. Subjects taking regular
inhaled corticosteroids continued to do so without any dose
change during the study. There was a balanced number of
subjects with high and low at baseline (>50 ppb and
<30 ppb respectively). These FENO cut-points were chosen
because they correspond to mean levels associated with
steroid responsiveness2 or are at the upper limit of normal
in patients with stable asthma.20 Each subject gave written
informed consent and the protocol was approved by the
Lower South Island (NZ) Ethics Committee.
Subjects attended on three occasions at the same time of
day. At each study visit, themean of two FENOmeasurements
using a NIOX (Aerocrine, Solna, Sweden) chem-
iluminescence analyser (the “gold standard”) was initially
obtained. The NIOX was calibrated regularly in accordance
with the manufacturer’s instructions. The measurement
technique complied with ATS/ERS guidelines.21
The study design is described in Fig. 1. Subjects were
randomised into two groups (Group 1, n Z 8; Group 2,
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(1e24), and thus a total of 24 different sensor-analyser
combinations were evaluated. Group 1 patients were allo-
cated to undertake two FENO measurements from each of
12 NIOX MINO sensor-analyser combinations at each visit,
and Group 2 patients did likewise, using the same analysers
but 12 different sensors. The order in which the sensor-
analyser combinations were tested was randomised at each
visit. The mean of the two measured values was recorded.
The allocation of patients to sensor-analyser combinations
was fixed for the duration of the study. Identical study
procedures were undertaken at visits 2 and 3 after inter-
vening intervals of approximately 1 and 2 months.
Quality control procedures were carried out on each
NIOX MINO device according to the manufacturer’s
guidelines. These were:
1. External control: FENO results from a biological control
(whose FENO was in the range 5e40 ppb) were obtained
on the study day and compared with the mean of three
previous recordings. The result was required to be
within 10 ppb of the established mean value (3
occasions over 7 days). This was performed at each
study visit.
2. Nitric oxide-free air was sampled using the quality
control filter, to ensure that a result below the lower
limit of detection (<5 ppb) was achieved. This was
performed after every 45 actuations, or 7 days which-
ever came first.
3. Internal control: exhaled breaths were simulated using
an electronic signal at 15 ppb and 75 ppb i.e. normal
and high FENO levels. This was performed after 45
actuations or 7 days, whichever came first.
Spirometric measurements were obtained at the end of
each study visit: where a change in the FEV1 of more than
20% occurred between visits, the patient returned on
a separate day to ensure that any change in airflow did not
affect the FENO measurements.
Each sensor had a capacity to be used 300 times. To
identify whether reproducibility was dependent on
frequency of use rather than the time from manufacture, 6
of the 12 sensors in each of the two Groups were actuated
repeatedly between visits, such that a sufficient number of
actuations were still available at the final study visit. The
remaining 6 (of 12 in each of the two Groups) were used
only at the study visits and not in between times.Table 1 Demographic and clinical characteristics of the study
Number of subjects, n
Males/females
Mean age, years (range)
Ex-smokers (n, %)
Atopic (n, %)
FEV1, % predicted (SD)
Baseline FENO Geometric mean ppb (SD)
High FENO group Baseline FENO, geometric mean ppb (SD)
Low/normal FENO group Baseline FENO, geometric mean ppb (SD)Statistical analyses were performed to establish the coef-
ficients of variation and the limits of agreement for repeated
measurements for each of the sensor-analyser combinations.
This was undertaken using variance component models. The
limits of agreement were calculated using an extension of
Bland Altman analyses in order to accommodate multiple
comparisons (23 NIOX MINO sensor-analyser combinations
versus NIOX) i.e. 1.96 times the standard deviation of the
repeated measurements random factor. In order to assess
whether results using any of the NIOX MINO devices were
systematically higher or lower than those obtained using the
NIOX chemiluminescence analyser, the factor change for each
of the sensor-analyser combinations compared to the refer-
ence NIOX results was calculated. This was the mean of log10
FENO (NIOX)/log10 FENO (NIOX MINO
). All calculations were
done using Stata V10. Two post hoc analyses were performed.
Firstly, we compared the outcomes for subjects with low and
high baseline FENO independently of the Group to which they
were initially randomised. Secondly, we compared the CVand
limits of agreement between sensors which had been used on
multiple occasions between visits with those which had not.
Thiswas to ascertainwhethermultiple uses or prolonged shelf
life were factors contributing to changes in sensor reproduc-
ibility over time.
Results
Seventeen patients completed the study. In Group 1
(nZ 8), 3 had high FENO levels and 5 had low FENO levels. In
Group 2 (nZ 9), 6 had high FENO levels and 3 had low FENO
levels. Overall, there were 9 patients with high FENO at
baseline, and 8 with low FENO at baseline. Their charac-
teristics are shown in Table 1. The geometric mean FENO
was 36.4 ppb (95% C.I.: 23.8, 55.6), 36.4 ppb (95% C.I.:
24.4, 54.3), and 33.5 ppb (95% C.I.: 22.3, 50.3) at visits 1, 2
and 3 respectively. The maximum intra-individual change in
FENO (using the NIOX) between any two visits ranged from
2.8 to 66.8 ppb (mean 16.6  15.9 ppb).
One of the 24 NIOX MINO devices (I 21) was withdrawn
from further use when it began to yield lower than expected
readings and subsequently failed the external quality control
check. This was simultaneously identified by the internal
quality control check as an“errormessage”. The threshold for
the error message was set during manufacture to occur when
the measured signal was >10 ppb different from the quality
control signal. The performance characteristics of the
remaining 23 sensor-analyser combinations in comparisonsubjects.
All Group 1 Group 2
17 8 9
7/10 3/5 4/5
42 (14e72) 49 (36e72) 36 (14e69)
3 (18%) 2 (25%) 1 (11%)
16 (94%) 8 (100%) 8 (89%)
91.8% (17.4) 84.1% (14.5) 98.7% (16.9)
49.7 (36.6) 35.9 (26.7) 62.1 (41.0)
79.7 (22.1) (n Z 9) 66.7 (10.0) (n Z 3) 86.2 (24.3) (n Z 6)
16.0 (6.4) (n Z 8) 17.3 (7.4) (n Z 5) 13.8 (4.5) (n Z 3)
Table 2 Coefficients of variation (CV) and limits of agreement for the NIOX MINO using the NIOX as the “gold standard”. D ta were obtained using each of 23 NIOX MINO
devices in random order. Eight patients (Group 1) completed testing on 12 sensor-analyser combinations, and 9 patients comp ted testing on 11 devices comprising the same
analysers but different sensors (Group 2). Data for all 23 sensor-analyser combinations were pooled. The factor change describe the magnitude of the difference between FENO
results obtained using the NIOX MINO with the NIOX chemiluminescence analyser as the “gold standard”. Factor change as calculated as: log10 FENO (NIOX)/log10 FENO
(MINO). Where the NIOX MINO gave a higher reading than the NIOX, the factor is <1. Numbers in brackets are ranges.
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Table 3 Coefficients of variation (CV) and limits of agreement for each of the 23 NIOX MINO sensor/analyser combinations,
using the NIOX as the “gold standard”. Eight patients completed testing on 12 sensor-analyser combinations (A1-L12), and 9
patients completed testing on 11 devices comprising the same analysers but different sensors (A13-L24). The analysers are
designated as capital letters, the sensors are designated as numbers (column 1). The factor change describes the magnitude of
the difference between FENO results obtained using the NIOX MINO
 with the NIOX chemiluminescence analyser as the “gold
standard”. Factor change was calculated as: log10 FENO (NIOX)/log10 FENO (MINO). Where the factor change is <1, then the NIOX
























A 1 3.7 2.6 1.016 7.0 5.1 0.984 3.8 2.2 1.005
B 2a 2.4 1.8 0.979 3.0 2.5 0.955 2.7 1.7 0.978
C 3a 2.8 2.2 0.972 4.1 3.5 0.941 2.1 1.3 0.979
D 4 5.6 4.0 0.998 2.2 1.6 0.981 7.6 4.3 1.008
E 5 2.6 2.0 0.964 3.1 2.5 0.946 2.7 1.7 0.973
F 6a 1.3 0.9 1.006 3.3 2.4 1.003 3.1 1.8 1.007
G 7a 2.4 1.6 1.012 4.5 3.4 0.967 2.6 1.5 1.010
H 8a 5.2 3.5 1.039 3.1 2.3 0.983 2.1 1.2 1.019
I 9 4.4 3.1 1.007 3.1 2.4 0.969 4.8 2.8 0.995
J 10 1.9 1.5 0.948 3.1 2.7 0.940 2.8 1.9 0.951
K 11a 6.0 4.4 0.958 2.0 1.6 0.940 4.7 2.7 0.951
L 12 2.7 1.8 1.024 2.7 1.9 1.008 5.4 3.0 1.017
A 13 5.2 7.0 0.980 3.1 4.0 0.969 5.2 6.4 0.979
B 14a 1.2 1.7 0.953 5.3 6.9 0.965 3.2 4.3 0.950
C 15a 7.2 9.6 0.973 2.5 3.3 0.954 3.3 4.2 0.963
D 16 4.3 5.4 0.991 2.8 3.4 0.982 5.7 6.8 1.006
E 17 4.6 6.7 0.957 3.4 4.8 0.936 5.0 6.8 0.943
F 18a 5.5 7.5 0.967 3.5 4.7 0.950 1.6 2.1 0.959
G 19a 3.4 4.3 1.009 4.9 6.0 1.008 2.8 3.3 0.979
H 20a 6.9 9.2 0.983 5.3 6.6 0.970 2.5 3.2 0.973
I 21 Withdrawn
J 22 3.5 4.5 0.972 4.5 6.0 0.942 3.1 4.1 0.940
K 23a 6.0 8.3 0.972 4.4 6.1 0.942 2.8 3.8 0.940
L 24 2.5 3.5 0.971 2.4 3.2 0.946 2.5 3.3 0.958
Mean 4.0 4.2 0.985 3.6 3.8 0.964 3.6 3.2 0.978
a designates sensor-analyser combinations which were used frequently in between visits.
Performance characteristics of the NIOX MINO 215with the NIOX chemiluminescence analyser are shown in
Table 2. More detailed data are provided in Table 3.
Overall, the NIOX MINO devices provided data whose
reproducibility was within clinically acceptable limits
(10 ppb). At visit 1, the mean coefficient of variation (CV)
for repeated measurements (23 sensor-analyser combina-
tions) was 4.0% (range 1.2e7.2%). There was no significant
change in mean CV over time: at visit 2 (approximately one
month) the mean CV was 3.6% (range 2.0e7.0) and at visit 3
(approximately two months) it was 3.6% (range 1.6e7.6%).
The 95% confidence interval for the limits of agreement for
FENO was similarly stable. At baseline the mean value was
4.2 ppb (range 0.9e9.6 ppb), at visit 2 it was 3.8 ppb
(range 1.6e6.9 ppb) and at visit 3 it was 3.2 ppb (range
1.2e6.8 ppb). The overall changes with time were not
statistically significant. The number of individual sensor-
analyser combinations for which the limits of agreement
exceeded the manufacturer’s specifications (5 ppb for the
low FENO group; 10% for the high FENO group) was 0 at visit
1, 3 at visit 2(13%) and 5 at visit 3(22%).
Comparisons for the CV and the 95% confidence intervals
for the limits of agreement between patients with high andlow baseline FENO are also shown in Table 2. Whereas at
baseline there were no significant differences, the results
at visit 2 and visit 3 were significantly different. The
coefficients of variation were significantly lower and the
limits of agreement were significantly higher in the high
FENO group (p < 0.001 for both).
Comparisons between the sensor-analyser combinations
which were used frequently over the study interval (approx-
imately 270 times) versus those used only intermittently
(approximately100 times) revealed that, at visit 3, therewere
significant differences in the CV and marginally significant
differences in the limits of agreement. In the frequently used
devices the CV was 1.6% lower (95% CI -0.6e2.7, pZ 0.005)
than in the intermittently used devices. The limits of agree-
ment were 1.3 ppb lower (95% CI -0.02e2.7, pZ 0.053) in
the frequently used devices (see Table 2).Discussion
In this study we evaluated the long term performance char-
acteristics of NIOX MINO, a portable nitric oxide analyser. By
216 D.R. Taylor et al.providingdataon23 sensor-analyser combinations,our results
answer the questions: on average what is the within-patient
performance for any NIOXMINO devicewhich Imay be using?
And, what might happen to performance characteristics over
time or when the sensor is changed?
We found that the mean limits of agreement for
repeated within-subject measurements averaged  4 ppb,
with a maximum of 9.6 ppb. This is almost identical to the
limits of agreement for repeated FENO measurements in
patients with stable asthma first reported by Kharitonov
et al. (4 ppb) using the NIOX chemiluminescence analy-
ser.20 In our study, the CV was approximately 4% with
a maximum of 8% which is less than the changes in FENO
which are considered clinically important (40%4). Thus,
overall, the performance characteristics of the NIOX MINO
were satisfactory. However, for some individual sensor-
analyser combinations, the manufacturer’s specified limits
of agreement (5 ppb for patients with low FENO and 10%
for those with high FENO) were exceeded. This occurred in
0 devices at visit 1, 3(13%) at one month, and 5(22%) at two
months. Using clinical rather than technical criteria for the
threshold at which quality control was assessed (10 ppb),
one device failed and was withdrawn from further use. This
occurred after approximately 3 months. Thus the overall
judgment on the performance characteristics of the MINO is
related to what is deemed to be an acceptable threshold
for reproducibility (5 ppb or  10 ppb).
Our data extend the results of previous inves-
tigations.5,9e19 Alving et al. reported 95% limits of agree-
ment of 9.8 to þ8.0 ppb,9 while Boot et al. reported limits
of agreement of 9.5 to þ7.4 ppb10In most studies using
the NIOX MINO, the limits of agreement for within-subject
comparisons against a chemiluminescence analyser have
been similar (maximum  9.6 ppb). However, almost all of
them used only single NIOX MINO devices in their
comparisons, and no distinctions were made between the
sensor and the analyser. For example, Menzies et al.,16
compared a single NIOX MINO device against the NIOX
in 151 subjects, but unfortunately the sensors were
changed periodically. The total number of sensors used and
the time at which they were replaced was not stated. In the
study by Khalili et al.14 three NIOX MINO devices were
used in 110 subjects, but no between-device comparisons
were made in their analyses. In the present study, a total of
23 sensor-analyser combinations were tested without any
of the sensors being changed during the course of the study.
This approach ensured that any between-sensor variation
was accounted for.
As far as we are aware, this is the first study to evaluate
the stability of the NIOX MINO over time. This is impor-
tant for NO analysers based on electrochemical tech-
nology. Firstly, we conducted measurements using
multiple sensor-analyser combinations at baseline, and at
one month and two months. As can be seen from Table 2,
there was no evidence of a systematic change in perfor-
mance with time, although there was an increase from
zero in the number of devices which exceeded the
performance limits set by the manufacturer. We also
explored the possibility that reproducibility might vary
depending on frequency of use rather than in relation to
chronological age. This was found to be the case: the CV
and the limits of agreement were significantly different attwo months in devices which were used frequently (up to
270 times) compared to those which were not (up to 100
times). However, the magnitude of the difference was not
clinically important (<10 ppb).
Previous authors have indicated the possibility of
systematic bias when comparing FENO values obtained using
the NIOX MINO against those obtained using chem-
iluminescence analysers.5,10,13,15,18 In one report FENO
measurements were so much higher with the NIOX MINO
that a correction factor was recommended.18 However, in
these reports the results were obtained using one NIOX
MINO device only. In our study, although results from all 23
NIOX MINO sensor-analyser combinations were on average
higher than those obtained using the NIOX (i.e. factor
change <1.0, see Table 2), the pattern was not consistent
and the differences were not significant. In our study, the
differences between the NIOX and the NIOX MINO ranged
maximally from 4% to þ6% (NS). We cannot account for
the very large between-device difference reported by Piz-
zimenti et al.18
It has been reported that CVs and limits of agreement are
greater when measuring high rather than low FENO values.
15
Persistently high FENO may occur in some patients even
with well controlled asthma, and changes over time may be
more important than absolute values, hence the importance
of obtaining reproducible results.22 Our data showed that the
limits of agreement were significantly higher in the high FENO
group (>50 ppb). The mean values for the limits of agree-
ment were acceptable (<10 ppb), but the 95% confidence
intervals for the limits of agreement extended to 19.8 ppb
(see Table 2). This indicates that when measuring FENO in
patients for whom the value is high, % change rather than
absolute change is more reliable.
The implications of these data depends on the setting in
which the NIOX MINO is being used. For the clinician,
single measurements may be used diagnostically, and
depend on the relationship between the measured value
and specific cut-points (25 ppb and 50 ppb respectively1).
The clinician has to consider whether allowing for variation
of 10 ppb will render a particular result either falsely
negative or falsely positive. When monitoring asthma,
changes in FENO over time are more important. In this
regard, even if an electrochemical sensor demonstrates
“signal drift” over time, the “drift” as reported in this
paper, is generally less than the changes which are deemed
to be clinically significant (30e40%).4,23 For research
purposes, quality control should be more rigorous, and we
recommend that for multicentre or longitudinal studies,
each sensor/analyser combination ought to be validated
against a calibrated chemiluminescence analyser, and
validation procedures, as described above, should be
repeated at regular intervals during the lifetime of each
sensor.
In summary, the reproducibility of FENO valuesmeasured in
23 NIOX MINO nitric oxide analysers was generally within
prescribed limits and stable over time. The overall outcomes
did not differ significantly in patients with high FENO levels.
Although differences in longitudinal reproducibility emerged
in deviceswhichwere used infrequently between testing, and
in 22% of sensor-analyser combinations the results were
outside the manufacturer’s specifications at 2 months, they
remained within 10 ppb of the “gold standard”.
Abbreviations
CI Confidence interval
CV Coefficient of variation
FENO The fraction of nitric oxide in exhaled air
FEV1 Forced expiratory volume in 1 s
ppb Parts per billion
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